0 10 Inhibition Inhibition NNP 11 13 of of IN 14 21 nuclear nuclear JJ 22 28 factor factor NN 29 34 kappa kappa NN 35 36 B B NNP 37 44 subunit subunit NN 45 48 p65 p65 NN 49 53 mRNA mrna NN 54 66 accumulation accumulation NN 67 69 in in IN 70 99 lipopolysaccharide-stimulated lipopolysaccharide-stimulated JJ 100 105 human human JJ 106 115 monocytic monocytic JJ 116 121 cells cell NNS 122 129 treated treat VBN 130 134 with with IN 135 141 sodium sodium NN 142 152 salicylate salicylate NN 152 153 . . . 155 173 Lipopolysaccharide Lipopolysaccharide NNP 174 176 is be VBZ 177 180 one one CD 181 183 of of IN 184 187 the the DT 188 192 most most RBS 193 199 potent potent JJ 200 207 trigger trigger NN 208 218 substances substance NNS 219 222 for for IN 223 232 monocytes monocyte NNS 233 236 and and CC 237 248 macrophages macrophage NNS 249 256 causing cause VBG 257 266 secretion secretion NN 267 269 of of IN 270 282 inflammatory inflammatory JJ 283 292 mediators mediator NNS 293 297 such such JJ 298 300 as as IN 301 306 tumor tumor NN 307 315 necrosis necrosis NN 316 322 factor factor NN 323 326 and and CC 327 340 interleukin-1 interleukin-1 NN 340 341 . . . 342 345 The the DT 346 352 nature nature NN 353 355 of of IN 356 359 the the DT 360 367 nuclear nuclear JJ 368 375 factors factor NNS 376 384 involved involve VBN 385 387 in in IN 388 398 regulation regulation NN 399 401 of of IN 402 407 these these DT 408 416 cytokine cytokine NN 417 422 genes gene NNS 423 425 is be VBZ 426 431 still still RB 432 439 unknown unknown JJ 439 440 . . . 441 448 Nuclear nuclear JJ 449 455 factor factor NN 456 461 kappa kappa NN 462 463 B B NNP 464 465 ( ( ( 465 473 NF-kappa NF-kappa NNP 474 475 B B NNP 475 476 ; ; : 477 488 heterodimer heterodimer NN 489 491 of of IN 492 495 p50 p50 NN 496 499 and and CC 500 503 p65 p65 NN 503 504 ) ) ) 505 513 proteins protein NNS 514 518 have have VBP 519 523 been be VBN 524 533 suggested suggest VBN 534 536 to to TO 537 541 play play VB 542 544 an an DT 545 554 important important JJ 555 559 role role NN 560 562 in in IN 563 567 gene gene NN 568 581 transcription transcription NN 582 584 of of IN 585 597 inflammatory inflammatory JJ 598 607 mediators mediator NNS 608 612 when when WRB 613 622 monocytes monocyte NNS 623 626 are be VBP 627 637 stimulated stimulate VBN 638 642 with with IN 643 661 lipopolysaccharide lipopolysaccharide NN 661 662 . . . 663 675 Nonsteroidal nonsteroidal JJ 676 693 anti-inflammatory anti-inflammatory JJ 694 699 drugs drug NNS 700 704 such such JJ 705 707 as as IN 708 719 salicylates salicylate NNS 720 724 have have VBP 725 729 been be VBN 730 734 used use VBN 735 737 to to TO 738 743 treat treat VB 744 752 symptoms symptom NNS 753 755 of of IN 756 768 inflammation inflammation NN 768 769 , , , 770 773 and and CC 774 775 a a DT 776 779 new new JJ 780 789 mechanism mechanism NN 790 792 of of IN 793 797 drug drug NN 798 804 action action NN 805 808 was be VBD 809 818 suggested suggest VBN 819 827 recently recently RB 827 828 . . . 829 840 Salicylates salicylate NNS 841 845 have have VBP 846 850 been be VBN 851 856 shown show VBN 857 859 to to TO 860 867 inhibit inhibit VB 868 894 lipopolysaccharide-induced lipopolysaccharide-induced JJ 895 899 gene gene NN 900 913 transcription transcription NN 914 917 via via IN 918 928 inhibition inhibition NN 929 931 of of IN 932 940 NF-kappa NF-kappa NNP 941 942 B B NNP 943 953 activation activation NN 954 956 by by IN 957 967 preventing prevent VBG 968 971 the the DT 972 983 degradation degradation NN 984 986 of of IN 987 995 NF-kappa NF-kappa NNP 996 997 B B NNP 998 1007 inhibitor inhibitor NN 1008 1009 “ `` `` 1009 1010 I i NN 1011 1016 kappa kappa NN 1017 1018 B B NNP 1018 1019 ” '' '' 1019 1020 , , , 1021 1029 blocking block VBG 1030 1033 the the DT 1034 1047 translocation translocation NN 1048 1050 of of IN 1051 1059 NF-kappa NF-kappa NNP 1060 1061 B B NNP 1062 1066 into into IN 1067 1070 the the DT 1071 1078 nuclear nuclear JJ 1079 1090 compartment compartment NN 1090 1091 . . . 1092 1099 However however RB 1099 1100 , , , 1101 1104 the the DT 1105 1111 nature nature NN 1112 1114 of of IN 1115 1118 the the DT 1119 1126 subunit subunit NN 1127 1135 involved involve VBN 1136 1138 in in IN 1139 1143 this this DT 1144 1153 mechanism mechanism NN 1154 1157 has have VBZ 1158 1161 not not RB 1162 1166 been be VBN 1167 1174 defined define VBN 1174 1175 . . . 1176 1178 To to TO 1179 1186 examine examine VB 1187 1190 the the DT 1191 1201 mechanisms mechanism NNS 1202 1204 by by IN 1205 1210 which which WDT 1211 1222 salicylates salicylate NNS 1223 1229 affect affect VBP 1230 1238 cytokine cytokine NN 1239 1243 gene gene NN 1244 1257 transcription transcription NN 1257 1258 , , , 1259 1262 the the DT 1263 1269 amount amount NN 1270 1272 of of IN 1273 1279 active active JJ 1280 1283 and and CC 1284 1292 inactive inactive JJ 1293 1301 NF-kappa NF-kappa NNP 1302 1303 B B NNP 1304 1307 and and CC 1308 1316 NF-kappa NF-kappa NNP 1317 1318 B B NNP 1319 1323 mRNA mRNA NNP 1323 1324 , , , 1325 1327 in in IN 1328 1341 Porphyromonas Porphyromonas NNP 1342 1352 gingivalis gingivalis NN 1353 1382 lipopolysaccharide-stimulated lipopolysaccharide-stimulated JJ 1383 1388 human human JJ 1389 1398 monocytic monocytic JJ 1399 1404 cells cell NNS 1405 1408 was be VBD 1409 1417 assessed assess VBN 1417 1418 . . . 1419 1423 High high JJ 1424 1429 doses dose NNS 1430 1432 of of IN 1433 1439 sodium sodium NN 1440 1450 salicylate salicylate NN 1451 1461 suppressed suppress VBD 1462 1470 NF-kappa NF-kappa NNP 1471 1472 B B NNP 1473 1476 p65 p65 NN 1477 1481 mRNA mrna NN 1482 1494 accumulation accumulation NN 1494 1495 , , , 1496 1505 resulting result VBG 1506 1508 in in IN 1509 1520 suppression suppression NN 1521 1523 of of IN 1524 1529 total total JJ 1530 1538 NF-kappa NF-kappa NNP 1539 1540 B B NNP 1540 1541 , , , 1542 1545 p50 p50 NN 1546 1548 on on IN 1549 1555 tissue tissue NN 1556 1571 oligonucleotide oligonucleotide NN 1572 1575 had have VBD 1576 1578 no no DT 1579 1586 effects effect NNS 1587 1589 on on IN 1590 1616 lipopolysaccharide-induced lipopolysaccharide-induced JJ 1617 1625 NF-kappa NF-kappa NNP 1626 1627 B B NNP 1628 1638 activation activation NN 1638 1639 . . . 1640 1643 The the DT 1644 1648 data datum NNS 1649 1660 demonstrate demonstrate VBP 1661 1665 that that IN 1666 1669 the the DT 1670 1673 p65 p65 NN 1674 1681 subunit subunit NN 1682 1684 of of IN 1685 1693 NF-kappa NF-kappa NNP 1694 1695 B B NNP 1696 1698 is be VBZ 1699 1708 inhibited inhibit VBN 1709 1711 by by IN 1712 1722 salicylate salicylate NN 1723 1732 treatment treatment NN 1733 1736 and and CC 1737 1746 highlight highlight VBP 1747 1750 the the DT 1751 1755 role role NN 1756 1758 of of IN 1759 1769 salicylate salicylate NN 1770 1772 in in IN 1773 1776 the the DT 1777 1784 control control NN 1785 1787 of of IN 1788 1792 gene gene NN 1793 1803 expression expression NN 1804 1806 of of IN 1807 1819 inflammatory inflammatory JJ 1820 1829 mediators mediator NNS 1829 1830 . . .